Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF: insights from the STEP-HFpEF programme

Back

HFA Premium Access

Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF: insights from the STEP-HFpEF programme

Session: Late breaking clinical trials: further analyses and baseline characteristics

Topic: Pharmacotherapy

Speaker: Professor M. Petrie (Glasgow, GB)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Professor Mark Petrie

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

47 presentations

8 followers

9 more presentations in this session

Effect of IV iron in patients with heart failure with preserved ejection fraction

Speaker: Professor S. von Haehling (Goettingen, DE)

Access

Slides

Video

Discussant review - FAIR-HFpEF

Speaker: Professor P. Kalra (Portsmouth, GB)

Access

Slides

Video

Discussant review - STEP HFpEF Program

Speaker: Doctor A. Bayes Genis (Badalona, ES)

Access

Slides

Video

Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access

Slides

Video

Discussant review - REALIZE-K

Speaker: Professor G. Rosano (London, GB)

Access

Slides

Video

Access the full session

Late breaking clinical trials: further analyses and baseline characteristics

Speakers: Professor M. Petrie, Professor S. von Haehling, Professor P. Kalra, Doctor A. Bayes Genis, Doctor M. Kosiborod...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources